Skinvisible, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021
June 15, 2021 at 04:26 pm EDT
Share
Skinvisible, Inc. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was USD 12,051 compared to USD 16,052 a year ago. Operating loss was USD 111,127 compared to USD 129,992 a year ago. Net loss was USD 435,505 compared to USD 430,084 a year ago. Basic loss per share from continuing operations was USD 0.1 compared to USD 0.1 a year ago.
Skinvisible, Inc., through its wholly owned subsidiary Skinvisible Pharmaceuticals Inc., is a pharmaceutical research and development (R&D) company. The Company is engaged in developing and patenting a polymer delivery system, Invisicare and formulated over forty topical skin products. The Company's product, Pivotal, is a patented polymer delivery system technology Invisicare. Invisicare is a patented polymer delivery system that enhances the delivery of active ingredients for topically applied skin care products. Its patented technology has a formula and process for combining active ingredients with a delivery system that extends the duration of time the product remains on the skin and active. Invisicare is specifically formulated to carry water-insoluble active and certain cationic active ingredients in water-based products without the use of alcohol, silicones, waxes, or other organic solvents.
SKINVISIBLE, INC. 
